Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
Delayed Swiss Exchange  -  11:31 2022-11-29 am EST
0.0286 CHF   -3.38%
11/21APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
EQ
11/16Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
EQ
11/14Relief Therapeutics, NRx Pharmaceuticals Sign Deal to Resolve Aviptadil Dispute
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Relief Therapeutics Holding AG Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa At Ann & Robert H. Lurie Children's Hospital of Chicago

09/22/2022 | 01:30am EST

Relief Therapeutics Holding AG announced that an Investigator Initiated Trial with Nexodyn for Epidermolysis Bullosa (EB) has received IRB approval and will shortly enroll participants at Ann & Robert H. Lurie Children's Hospital of Chicago with Professor Amy Paller, M.D., Chair, Department of Dermatology, Feinberg School of Medicine, Northwestern University, serving as Principal Investigator. This trial represents an important step in the clinical development pathway of Relief's APR-TD011, a pharmaceutical grade hypochlorous acid topical spray being evaluated for decolonization, symptom alleviation, and healing of EB wounds.


ę S&P Capital IQ 2022
All news about RELIEF THERAPEUTICS HOLDING AG
11/21APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the ..
EQ
11/16Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 wit..
EQ
11/14Relief Therapeutics, NRx Pharmaceuticals Sign Deal to Resolve Aviptadil Dispute
MT
11/14Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Defi..
EQ
11/08Relief Therapeutics, NRx Further Extend Stay of Pending Aviptadil Dispute
MT
11/08Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay ..
EQ
11/07Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation ..
CI
11/07Relief Therapeutics' New Aviptadil Formulation Found To Be Stable In Six-month Data
MT
11/07Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 ..
EQ
10/26Relief Therapeutics, NRx Extend Stay For Pending Aviptadil Dispute
MT
More news
Financials
Sales 2021 3,32  3,49  3,49 
Net income 2021 -34,7 M -36,5 M -36,5 M
Net cash 2021 40,5 M 42,5 M 42,5 M
P/E ratio 2021 -6,44x
Yield 2021 -
Capitalization 126 M 132 M 132 M
EV / Sales 2020 -
EV / Sales 2021 70 411 988x
Nbr of Employees 10
Free-Float 65,6%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 0,03
Average target price
Spread / Average Target -
Managers and Directors
Jack M. Weinstein Chief Financial Officer & Treasurer
Raghuram Selvaraju Chairman
Nermeen Varawalla Chief Medical Officer
Paolo Galfetti Chief Operating Officer & Director
Thomas Plitz Director
Sector and Competitors
1st jan.Capi. (M$)
RELIEF THERAPEUTICS HOLDING AG-52.41%137
MODERNA, INC.-30.95%67 378
IQVIA HOLDINGS INC.-23.99%39 832
LONZA GROUP AG-34.32%39 180
ALNYLAM PHARMACEUTICALS, INC.23.36%25 738
SEAGEN INC.-21.59%22 506